07 Abr Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" css=".vc_custom_1584737067410{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}" z_index=""][vc_column css=".vc_custom_1584737077948{margin-top: 0px !important;}"][vc_column_text css=".vc_custom_1588091973445{margin-top: 0px !important;padding-top: 0px !important;}"]Andrew M. South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath and Matthew A. Sparks[/vc_column_text][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"...